Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Auris Medical to Host Corporate Symposium on Rational Pharmacotherapy for Acute Hearing Loss on September 28, 2015

CYTOF

ZUG, Switzerland, Sept. 25, 2015 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will host a corporate symposium at the Annual Meeting of the American Academy of Otolaryngology-Head and Neck Surgery Foundation (AAO-HNSF).[1] The symposium on "Rational Pharmacotherapy for Acute Hearing Loss - Recent Advances and Perspectives" will take place on September 28, 2015, at 6.15 p.m. CDT at the Omni Hotel in Dallas TX.

The symposium will be chaired by Lawrence R. Lustig, MD, Howard W. Smith Professor and Chairman of the Department of Otolaryngology Head and Neck Surgery at the Columbia University Medical Center, New York. The program will feature talks on:

  • Hearing Preservation Following Acute Cochlear Stress Injury; Adrien E. Eshraghi, MD, University of Miami Ear Institute
  • Drug Delivery to the Inner Ear; Hinrich Staecker, MD, PhD, University of Kansas Medical Center
  • Clinical Trials in Acute Hearing Loss; Steven D. Rauch, MD, Harvard Medical School
  • Efficacy Outcomes in Hearing Loss Clinical Trials; Christopher F. Halpin, PhD, Harvard Medical School

Webcasts of the presentations will be available through the Events and Presentations page in the Investors section of the Company's website (www.aurismedical.com) within 48 hours after the event.

About Auris Medical

Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland.

[1] This event is not part of the official AAO-HNSF 2015 Annual Meeting & OTO EXPOSM.

Auris Medical Acute Hearing Loss Symposium 2015-09-25 http://hugin.info/160190/R/1954527/711319.pdf

HUG#1954527

CONTACT: Company: 
         Dr. Thomas Meyer, Chairman and CEO, 
         +41 41 729 71 94, ear@aurismedical.com
         
         Investors: 
         Matthew P. Duffy, Managing Director, LifeSci Advisors, 
         212-915-0685, matthew@lifesciadvisors.com

Auris Medical AG logo



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today